Jennison Associates
IRON icon

Jennison Associates’s Disc Medicine IRON Stock Holding History

Jennison Associates’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39M Buy
610,382
+78,303
+15% +$5.43M 0.03% 253
2025
Q4 		$42.3M Buy
+532,079
New +$45M 0.03% 238
2024
Q2 		– Sell
-193,240
Closed -$12M – 590
2024
Q1 		$12M Buy
193,240
+150,209
+349% +$9.74M 0.01% 384
2023
Q4 		$2.49M Buy
+43,031
New +$2.2M ﹤0.01% 448

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jennison Associates's IRON Position: Q1 2026 in Review

Jennison Associates increased its Disc Medicine (IRON) stake by 15% in Q1 2026, buying an estimated $5.43M and bringing the position to 610,382 shares worth $39M. The position accounts for 0.03% of the portfolio, ranked #253.

Jennison Associates first reported a position in IRON in Q4 2023 and has held it in 4 quarters since. The position peaked at $42.3M in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Jennison Associates held 610,382 shares of Disc Medicine worth $39M as of Q1 2026.
  • Jennison Associates bought 78,303 Disc Medicine shares in Q1 2026, an estimated $5.43M.
  • Disc Medicine made up 0.03% of Jennison Associates's portfolio in Q1 2026, its #253 holding.
  • Jennison Associates first reported a position in Disc Medicine in Q4 2023 and has held it in 4 quarters since.
  • Jennison Associates's Disc Medicine position peaked at $42.3M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.